{"id":"NCT01566721","sponsor":"Hoffmann-La Roche","briefTitle":"A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","officialTitle":"A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-17","primaryCompletion":"2015-03-10","completion":"2020-02-19","firstPosted":"2012-03-29","resultsPosted":"2017-04-18","lastUpdate":"2021-04-27"},"enrollment":2577,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"Herceptin","otherNames":["Trastuzumab"]}],"arms":[{"label":"Cohort A: SC Herceptin by Needle/Syringe","type":"EXPERIMENTAL"},{"label":"Cohort B: SC Herceptin by SID","type":"EXPERIMENTAL"}],"summary":"This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).","primaryOutcome":{"measure":"Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period","timeFrame":"From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)","effectByArm":[{"arm":"Cohort A: SC Herceptin by Needle/Syringe","deltaMin":88.6,"sd":null},{"arm":"Cohort B: SC Herceptin by SID","deltaMin":89,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":437,"countries":["Albania","Algeria","Argentina","Australia","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","Colombia","Croatia","Czechia","Dominican Republic","Ecuador","Egypt","El Salvador","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Indonesia","Ireland","Italy","Lithuania","Malaysia","Mexico","Morocco","Netherlands","New Zealand","Norway","Pakistan","Panama","Peru","Philippines","Poland","Portugal","Romania","Russia","Saudi Arabia","Serbia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Arab Emirates","United Kingdom","Uruguay","Venezuela","Vietnam"]},"refs":{"pmids":["30018134","28625777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":242,"n":1864},"commonTop":["Fatigue","Diarrhoea","Arthralgia","Nausea","Myalgia"]}}